New GSK WKN: A3DMB5 ISIN: GB00BN7SWP63 Kürzel: GS71 Forum: Aktien User: o2kuh

Nichts für ungut... Aber wenn man hier in das forum schaut und dein (sinnloses) Gespamme alle paar Minuten sieht, gehörst du damit schon in die Kategorie -> verhaltensauffällig. Kümmere dich vielleicht erstmal darum/ um dich, bevor du dich mit Aktien auseinander setzt.

Deal:)

Bei Stock3 in der App als Kurznachricht 😉

Warum die heftige Reaktion? Es war doch klar, dass es schwierig wird

15,64 EUR -5,01 % -0,83

15,75 €

Bitte um Link(s)

Wo hattest du das so schnell gefunden?

A group of independent advisors to the U.S. Food and Drug Administration (FDA) on Thursday voted against the approval of a combination drug regimen involving GSK’s (NYSE:GSK) blood cancer medicine Blenrep. Shares of the British pharma giant lost ~5% in reaction. The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5-3 against the benefit-risk profile of Blenrep in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma as a late-line therapy. The panelists voted 7-1 against the drug’s benefit-risk profile with pomalidomide and dexamethasone for the same indication. Bortezomib and pomalidomide are FDA-approved cancer drugs marketed by Johnson & Johnson (JNJ) and Bristol Myers (BMY) as Velcade and Pomalyst, respectively. Dexamethasone is a widely used anti-inflammatory agent. The London-based drugmaker's Biologics License Application, targeted at getting U.S. approval for the combination drug for R/R multiple myeloma as a late-line therapy, is currently under FDA review with a target action date of July 23. The FDA's advisory committees issue non-binding recommendations. However, the regulator generally follows them before making a final decision on authorizations.

GSK falls as FDA advisors vote against approving blood cancer drug

Bitte um direkten Link und den Ursprungslink

Wo hattest du die News so schnell her?

15,8 €

15,7 €

Gsk Stellungnahme?!